High efficacy of disopyramide in the management of ventricular fibrillation storms in a patient with Brugada syndrome.

Abstract

The patient was a 57-year-old man with Brugada syndrome, who had been implanted with a implantable cardioverter defibrillator (ICD). The frequency of ventricular fibrillation (VF) started to increase about 4 years after ICD implantation, occurring, at worst, six times in one night. Immediately after starting oral administration of disopyramide, VF stopped occurring. He then discontinued taking disopyramide, but immediately after the discontinuation VF started occurring again, so he restarted taking disopyramide. Thereafter, VF completely stopped occurring. Findings observed in our case suggest that disopyramide could be added in our arsenal of medications for treating arrhythmic storms in patient with Brugada syndrome.

• Authors: Shunichiro Sumi, Seiyo Maruyama, Yuhei Shiga, Sunao Kodama, Kei Miyoshi, Hideaki Tojou, Yoshio Yamanouchi, Hidenori Urata
• Journal: Pacing and clinical electrophysiology : PACE (Pacing Clin Electrophysiol) Vol. 33 Issue 6 Pg. e53-6 (Jun 01 2010) ISSN: 1540-8159 [Electronic] United States
• PMID: 20059716 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Disopyramide
• Quinidine

Topics

• Anti-Arrhythmia Agents (therapeutic use)
• Brugada Syndrome (drug therapy, therapy)
• Defibrillators, Implantable
• Disopyramide (therapeutic use)
• Electrocardiography
• Humans
• Male
• Middle Aged
• Quinidine (therapeutic use)
• Ventricular Fibrillation (drug therapy, therapy)